Intest Res > Volume 21(3); 2023 > Article |
|
Funding Source
The authors received no financial support for the research, authorship, and/or publication of this article.
Author Contribution
Conceptualization: Giri S. Methodology: Giri S, Agrawal D, Afzalpurkar S, Kasturi S, Gopan A. Formal analysis: Giri S, Kasturi S, Gopan A. Project administration: Giri S, Sundaram S, Kale A. Visualization: Giri S. Writing-original draft: Giri S, Agrawal D, Afzalpurkar S. Writing-review and editing: Giri S, Agrawal D, Afzalpurkar S, Sundaram S, Kale A. Approval of final manuscript: all authors.
Author (year) | Country | Study design | No. of patients | M/F | Age (yr), mean±SD | Patient selection | Risk factors (S/B) | Vaccine history |
---|---|---|---|---|---|---|---|---|
Longo et al. (2000) [18] | France | Prospective | 117 (43 UC/74 CD) | 53/64 | 41 ± 16 | Consecutive patients with IBD | - | - |
Biancone et al. (2001) [19] | Multicentric | Prospective | 489 IBD | - | 40 ± 13 | Consecutive patients with IBD | - | - |
Esteve et al. (2004) [20] | Spain | Prospective | 80 CD | 45/35 | 38.2 | Prior to anti-TNF therapy | - | - |
Tolentino et al. (2008) [21] | Brazil | Prospective | 176 (74 UC/102 CD) | 68/108 | - | Consecutive patients with IBD | 29.3/26.7 | - |
Agmon-Levin et al. (2009) [22] | Multicentric | Prospective | 98 IBD | - | - | Patients with autoimmune disease | - | - |
Lidar et al. (2009) [23] | Multicentric | Prospective | 119 (39 UC/80 CD) | - | - | NA | - | - |
Loras et al. (2009) [24] | Spain | Prospective | 2,076 (928 UC/1,128 CD/20 IBD-U) | 1,043/1,033 | 44.1 ± 0.32 | Consecutive patients with IBD | - | - |
Chevaux et al. (2010) [25] | France | Prospective | 315 (63 UC/252 CD) | - | 33.3 ± 14.1 | Consecutive patients with IBD | 33.7/ - | Yes |
Katsanos et al. (2010) [26] | Greece | Retrospective | 453 (308 UC/145 CD) | 255/198 | 40.8 ± 11.3 | Consecutive patients with IBD | 12.1/12.1 | - |
Morisco et al. (2012) [27] | Italy | Retrospective | 5,096 (2,611 UC/2,485 CD) | - | - | Consecutive patients with IBD | - | - |
Park et al. (2012) [28] | Korea | Retrospective | 4,153 (1,728 UC/1,521 CD) | 2,523/1,630 | 35.1 ± 8.4 | Consecutive patients with IBD | - | - |
Vaughn et al. (2012) [29] | USA | Retrospective | 287 (61 UC/223 CD/3 IBD-U) | 139/148 | 41.7 ± 12.3 | Only requiring anti-TNF therapy | - | - |
Kim et al. (2013) [30] | Korea | Prospective | 513 (272 UC/241 CD) | 330/183 | 37.3 ± 13.6 | Disease duration > 6 mo | 17.3/25.5 | Yes |
Papa et al. (2013) [31] | Italy | Prospective | 301 (117 UC/184 CD) | 142/159 | 41.9 ± 13.2 | Prior to anti-TNF therapy | 53.1/ - | Yes |
Ben Musa et al. (2014) [32] | USA | Retrospective | 500 (206 UC/292 CD/2 IBD-U) | 195/305 | 42.5 ± 16.5 | Consecutive patients with IBD | - | - |
Huang et al. (2014) [33] | China | Retrospective | 714 (317 UC/397 CD) | 415/299 | 37.2 ± 9.8 | Consecutive patients with IBD | 22/ - | Yes |
Loras et al. (2014) [34] | Spain | Prospective | 389 (82 UC/307 CD) | 205/184 | 40 ± 0.7 | Prior to anti-TNF therapy | - | Yes |
Sui et al. (2014) [35] | China | Retrospective | 256 UC | 127/119 | 50.8 ± 16.2 | Patients with UC | - | - |
van der Have et al. (2014) [36] | Netherlands | Retrospective | 611 CD | 215/396 | 32.9 ± 13.5 | Prior to anti-TNF therapy | - | - |
He et al. (2015) [37] | China | Retrospective | 675 (226 UC/449 CD) | 436/239 | - | Consecutive patients with IBD | - | Yes |
Chan et al. (2016) [38] | China | Retrospective | 406 (221 UC/185 CD) | 241/165 | 44.8 ± 13.5 | IBD duration > 3 mo | 14.3/ - | - |
Waszczuk et al. (2016) [39] | Poland | Prospective | 147 (63 UC/57 CD) | 79/68 | 38 ± 16 | Hospitalized IBD patients | - | Yes |
Ardesia et al. (2017) [40] | Italy | Retrospective | 509 (220 UC/289 CD) | 300/209 | 42.3 ± 11.5 | Patients screened for biologic and/or thiopurine therapy | - | - |
Chen et al. (2017) [41] | China | Retrospective | 980 (334 UC/646 CD) | 598/382 | 39.4 ± 15.5 | Hospitalized IBD patients | - | Yes |
Harsh et al. (2017) [42] | India | Retrospective | 908 (581 UC/327 CD) | 541/367 | 37.7 ± 12.5 | Consecutive patients with IBD | - | - |
Abid et al. (2018) [43] | Morocco | Retrospective | 755 (364 UC/391 CD) | 249/506 | 35.4 ± 11.6 | Consecutive patients with IBD | 19.7/22.2 | - |
Shah et al. (2018) [44] | USA | Retrospective | 3,357 (775 UC/1,954 CD/628 IBD-U) | 3,013/344 | 50.6 | Only requiring anti-TNF therapy | - | - |
Yeo et al. (2018) [45] | Korea | Prospective | 210 (109 UC/101 CD) | 133/77 | 34.9 ± 15.3 | Newly diagnosed IBD | - | Yes |
Chou et al. (2019) [46] | Taiwan | Retrospective | 190 (110 UC/80 CD) | 135/55 | 38.4 ± 15.9 | IBD duration > 3 mo | - | - |
Fousekis et al. (2019) [47] | Greece | Retrospective | 602 (346 UC/256 CD) | 360/242 | 39 ± 17.4 | Consecutive patients with IBD | - | - |
Silva et al. (2019) [48] | Brazil | Prospective | 306 (165 UC/141 CD) | 117/189 | - | Consecutive patients with IBD | - | - |
Losurdo et al. (2020) [49] | Italy | Prospective | 807 (369 UC/438 CD) | 474/333 | 46.2 ± 13.2 | Consecutive patients with IBD | - | Yes |
Sabbah et al. (2020) [50] | Tunisia | Prospective | 74 (12 UC/62 CD) | 36/38 | 43.5 ± 14.2 | Consecutive patients with IBD | - | - |
Patil et al. (2021) [51] | India | Prospective | 76 (42 UC/33 CD) | 48/28 | 37.5 ± 13.9 | Consecutive patients with IBD | 13.1/ - | - |